News: MRI and mammography for women at high risk for breast cancer

Article

Combining MRI and mammography for women at high risk for breast cancer.

Combining contrast-enhanced MRI screening with mammography may make sense for women with a known or likely genetic predisposition to breast cancer, according to the findings of a systematic literature review.

Researchers from Canada reviewed 11 relevant, prospective, nonrandomized studies. They calculated negative likelihood ratios and the probability of a BI-RADS–suspicious lesion (given negative test findings and assuming a 2% pretest probability of disease) to be 0.70 (95% CI, 0.59–0.82) and 1.4% (95% CI, 1.2%–1.6%) for mammography alone and 0.14 (95% CI, 0.05–0.42) and 0.3% (95% CI, 0.1%–0.8%) for MRI plus mammography. A BI-RADS score of 4 or higher was used to define positive.

Given that women who possess autosomal-dominant mutations in BRCA1 or BRCA2 genes are at up to 85% greater lifetime risk for breast cancer than other women, the added sensitivity of the dual screening strategy may be well worth the added expense.

Recent Videos
First US national HPV conference highlights advances in cancer prevention | Image Credit: uchealth.com.
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
1 expert is featured in this series.
Susanna Mitro, PhD, reveals ethnic disparities in uterine fibroid diagnosis | Image Credit: divisionofresearch.kaiserpermanente.org.
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Jihong Liu, ScD, explains how to improve perinatal outcomes in COVID patients | Image Credit: sc.edu.
1 expert is featured in this series.
Jihong Liu, ScD, highlights adverse perinatal outcomes linked to the COVID pandemic | Image Credit: sc.edu.
Experts highlight infant health benefits from minor diet changes in pregnancy | Image Credit: ohsu.edu.
Connie Stark, RNC, PNC, provides fertility preservation insights for endometriosis patients | Image Credit: linkedin.com.
© 2025 MJH Life Sciences

All rights reserved.